PranaX announced it has closed an oversubscribed $17 million Series A financing as the company scales its regenerative biologics work centered on stem cell-derived exosomes. The biotechnology company said the round was led by family offices, trusts, and individual investors with experience across biotechnology, regenerative medicine, and healthcare innovation.
The company framed the raise as coming amid growing attention to the exosome wellness sector, which proponents describe as an emerging area within regenerative medicine aimed at supporting healthy aging and quality of life. PranaX said it is developing exosome-based technologies and intends to advance the field through evidence-based science and what it described as responsible innovation and scientific rigor.
PranaX said it will use the proceeds to advance research and development, expand scientific and operational infrastructure, support strategic partnerships, and accelerate product development and commercialization efforts as it enters its next phase of growth.
Based in Houston, PranaX said its research, development, and manufacturing operations are headquartered within the Levit Green life science campus.
KEY QUOTE:
“PranaX was founded on the belief that exosomes can redefine how we approach aging and long-term wellness. We are building a science-driven platform that bridges rigorous biological understanding with real-world impact. This financing validates both our mission and our differentiated approach, and it positions us to scale thoughtfully while remaining grounded in scientific integrity.”
Steven J. Greco, PhD, Founder and Chief Operating Officer, PranaX
